Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: RBP7 functions as a tumor suppressor in HR + breast cancer by inhibiting the AKT/SREBP1 pathway and reducing fatty acid

Fig. 1

Expression and prognosis value of RBP7 in HR + BC. a Heatmap of the differentially expressed genes (DEGs) between HR + BC (G1) and normal tissues. Red: significantly up-regulated DEGs; blue: significantly down-regulated DEGs. b Venn diagram of 6 differentially expressed genes were found in the intersection of three databases. G1: DEGs between HR + BC and normal tissues from TCGA-BRCA dataset (n = 5175). G2: OS-associated genes (P<0.01, n = 203). G3: Immune-related genes screened from ImmPort data portal (n = 1793). c Univariate Cox regression analysis of the 6 DEGs. d Multivariate Cox regression analysis of the 6 DEGs. e RBP7 mRNA expression levels in TCGA HR + BC tumor tissues and TCGA and GTEX normal tissues. f RBP7 mRNA expression levels in HR + BC tumor tissues and para-tumor tissues in TCGA. g Distribution of the HR + BC patients based on risk scores and survival time and status of the HR + BC patients. Red: high risk groups; blue: low risk groups. h Kaplan-Meier survival curves of high- and low-RBP7 patients in HR + BC cohorts. i ROC curves with calculated AUCs for OS prediction in HR + BC.

Back to article page